Insulin Drug Pricing Report (Consumer Protection Act)
Current understanding
HB6132 would amend Michigan’s Consumer Protection Act (1976 PA 331) by adding sec. 9b to require the Department of Attorney General to produce a report on insulin drug pricing. Introduced; no substantive committee action reported yet. The measure treats insulin affordability as an unfair trade practices issue within existing consumer protection oversight rather than creating a new regulatory pathway.
Evidence log
- 2026-07-31 — Attorney General v Eli Lilly and Company: cross-connection with mcpa-regulated-industry-exemption: The Eli Lilly decision arose from the AG’s insulin-pricing investigation, tying the MCPA exemption scope directly to insulin drug pricing oversight. (novelty: 4)
Open questions
Related
Contributing findings
Consumer protection: unfair trade practices; insulin drug pricing report; require by the department of attorney general. Amends 1976 PA 331 (MCL 445.901 - 445.922) by adding sec. 9b.
25-jun-2026
novelty 2
per-area 2
introduces